Mustafa Erman

9.1k citations
133 papers · 7.1k · 4 hit papers · h-index 24

Impact in

  • Oncology top 0.5%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • Inflammatory Biomarkers in Disease Prognosis
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment

Papers in

    • Cancer Immunotherapy and Biomarkers 19
    • Inflammatory Biomarkers in Disease Prognosis 14
    • Lung Cancer Research Studies 4
    • Lung Cancer Treatments and Mutations 14
    • Renal cell carcinoma treatment 13
    • Prostate Cancer Treatment and Research 4

Mustafa Erman

112 papers receiving 6.9k citations

Mustafa Erman's Hit Papers

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial 2020 · 408 citations
4080+2+4Years since publication5001k1.5k2k2.5k

Peers

Mustafa Erman
Comparison fields: 5 of 90
  • Oncology 4.6k
  • Pulmonary and Respiratory Medicine 1.4k
  • Ophthalmology 157
  • Surgery 553
  • Cancer Research 158
Replace Cheolwon Suh with:
Cheolwon Suh South Korea
Maureen J.B. Aarts Netherlands
Justine Vanessa Cohen United States
Pierre Biron France
Thomas E. Olencki United States
Jorge Julio Castillo United States
Jan Willem B. de Groot Netherlands
Marcella M. Johnson United States
Brett W. Carter United States
Joel Jiang United States
Mustafa Erman relative to Cheolwon Suh South Korea Cheolwon Suh's profile →
Citations per field
00.5×2×3.0×
Cheolwon Suh · 1×
Citations per year

Countries citing papers authored by Mustafa Erman

Since Specialization
Citations

This map shows the geographic impact of Mustafa Erman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mustafa Erman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mustafa Erman more than expected).

Fields of papers citing papers by Mustafa Erman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mustafa Erman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mustafa Erman. The network helps show where Mustafa Erman may publish in the future.

Co-authors

The 25 scholars most cited alongside Mustafa Erman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mustafa Erman Line = papers co-authored together Mustafa Erman links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 133 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Hit paper breakdown →
20192712
2
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Hit paper breakdown →
20191737
3
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
Hit paper breakdown →
2020522
4
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Hit paper breakdown →
2020408
5 2021223
6 2017141
7 201973
8 200967
9 202254
10 200649
11 200748
12 200245
13
Interactions of nitric oxide and superoxide dismutase in Behçet's disease.
200241
14 200434
15 200734
16 202030
17
Synovial fluid cytokine levels in Behçet's disease.
200229
18 200427
19 200427
20 200826

About Mustafa Erman

Mustafa Erman is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Ophthalmology, Surgery and Geriatrics and Gerontology, having authored 133 papers that have together received 7.1k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (19 papers), Inflammatory Biomarkers in Disease Prognosis (14 papers), Lung Cancer Treatments and Mutations (14 papers), Renal cell carcinoma treatment (13 papers), Bladder and Urothelial Cancer Treatments (10 papers), Ocular Diseases and Behçet’s Syndrome (6 papers), Prostate Cancer Treatment and Research (4 papers) and Lung Cancer Research Studies (4 papers). The work is most often cited by research in Oncology (4.6k citations), Pulmonary and Respiratory Medicine (1.4k citations), Ophthalmology (157 citations), Surgery (553 citations) and Cancer Research (158 citations). Mustafa Erman has collaborated with scholars based in Türkiye, United States and France. Frequent co-authors include Sercan Aksoy, Saadettin Kılıçkap, Ismail Celik, Hüseyin Abalı, İhsan Ertenli, Sedat Kiraz, Meral Çalgünerı, İbrahim C. Haznedaroğlu, Deniz Can Guven and Hakan Harputluoğlu. Their work appears in journals such as Medical Oncology, Journal of Clinical Medicine, Lung Cancer, BMC Cancer and Clinical Genitourinary Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact